Autres langues Celltrion, Inc.

Actions

A068270

KR7068270008

Recherche biotechnologique et médicale

Cours en clôture Korea S.E. 04/09/2026			Varia. 5j.	Varia. 1 janv.
188 100,00 ^KRW	+0,53%		-1,36%	+9,12%

05:32	Celltrion obtient l'approbation d'amendements aux demandes d'IND pour les essais de phase 3 du CT-P44 et du CT-P51	MT
31/08	Celltrion, Inc. autorise un plan de rachat d'actions.	CI

Autres langues

06:29	Kospi in forte rialzo, volano i titoli dei chip
05:32	Celltrion Secures IND Application Amendment Approvals for CT-P44, CT-P51 Phase 3 Trial
31/08	Celltrion, Inc. authorizes a Buyback Plan.
31/08	Celltrion, Inc. announces an Equity Buyback for 524,384 shares.
31/08	Celltrion to Repurchase 100 Billion Won in Treasury Shares from Sept. 1
25/08	Celltrion Launches Omlyclo 300 Mg Strength In Key European Markets
24/08	Celltrion Submits Marketing Application for Keytruda Biosimilar in South Korea
18/08	Celltrion's Acquired French Healthcare Firm Becomes Fully Operational
14/08	Celltrion, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
04/08	Celltrion Files Phase 3 Trial Amendment for CT-P44 Biosimilar for Myeloma
27/07	Celltrion : Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability
24/07	Celltrion Submits EMA Marketing Authorization Application for Cosentyx Biosimilar CT-P55
24/07	Celltrion Submits Dual-Part EMA Application for Subcutaneous Rheumatoid Arthritis Drug
24/07	Celltrion Submits South Korean IND for Subcutaneous Rheumatoid Arthritis Drug
14/07	Celltrion Terminates, Withdraws EMA Trial Application for CT-P51 Biosimilar
07/07	Celltrion : Vegzelma completes formulary listings with two major U.S. PBMs, expanding reimbursement access to drive further U.S. growth
07/07	Celltrion Submits Amendment for Phase 3 Trial of Cancer Biosimilar to US FDA
03/07	South Korean Shares Jump on Bargain-Hunting, Chip Stock Gains
03/07	Celltrion's Sales Jump 35% in Q2; Shares Rise 4%
03/07	Celltrion : Reports Preliminary Q2 2026 Revenue of KRW 1.3Tn and Operating Profit of KRW 430Bn… Achieving Record-High Second-Quarter Performance, Raising Expectations for Full-Year Target Outperformance
03/07	Samsung, SK Hynix Lead KRW 392 Trillion Investment in South Korea's Chungcheong Region
30/06	Tranche Update on Celltrion, Inc.'s Equity Buyback Plan announced on May 21, 2026.
26/06	Celltrion, Inc.'s Equity Buyback announced on May 21, 2026, has closed with 586,927 shares, representing 0.26% for KRW 99,872.81 million.
19/06	South Korean Shares Snap Six-Day Winning Streak on Profit-Booking
19/06	Celltrion's EU Clinical Trial Nod for Crohn's Disease Drug Lapses